Search

Aim: In the respect of the benefits of TLC-NOSF in forefoot and midfoot neuro-ischaemic DFUs1, this current study aimed to evaluate the effectiveness of TLC-NOSF in the management of neuro-ischaemic heel DFUs. Method: This study is a retrospective single arm non-comparative study including consecutive patients with a non-infected neuro-ischaemic heel DFU (Grade IC or IIC of Texas University Classification, TUC). All patients were managed according to IWGDF Guidance2. After the revascularization of affected limb and the surgical removal of non-viable tissues, the local treatment with TLCNOSF was regularly performed. After 24 weeks of follow-up, the following outcomes were evaluated: wound healing, healing time (days), wound area regression (>50%), re-ulceration, and safety. Results / Discussion: Thirty patients were included. The mean age was 67±11 years, 17 (56.7%) were male, 30 (100%) were affected by type 2 diabetes with a mean duration of 18±7 years. Twenty patients (66.7%) had deep ulcers (TUC grade 2), the mean TcPO2 value after revascularization procedure was 42 ±7 mmHg. Twenty-two patients (73.3%) healed in a mean time of 84±32 days. Twenty-eight patients (93.3%) had wound regression, 2 (6.7%) had ulcer relapse after healing, 2 (6.7%) had mild infection, and 1 (3.3%) reported major amputation due to severe infection. No serious adverse events related to TLC-NOSF or local reactions were reported during the course of the study. Conclusion: The current study highlighted the potential benefit of TLC-NOSF also in the management of neuro-ischemic heel DFUs as a part of the integrated standard of care. [ABSTRACT FROM AUTHOR]